Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Improved antiviral efficacy using TALEN-mediated homology directed recombination to introduce artificial primary miRNAs into DNA of hepatitis B virus.

Biochemical and biophysical research communications - 30 Sept 2016

Dreyer Timothy, Nicholson Samantha, Ely Abdullah, Arbuthnot Patrick, Bloom Kristie

Abstract excerpt

Chronic infection with hepatitis B virus (HBV) remains an important global health problem. Currently licensed therapies have modest curative efficacy, which is as a result of their transient effects and limited action on the viral replication intermediate comprising covalently closed circular DNA (cccDNA). Gene editing with artificial HBV-specific endonucleases and use of artificial activators of the RNA...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to DNA, Viral

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hep G2 Cells

Share to Hepatitis B Surface Antigens

Share to Hepatitis B virus

Share to MicroRNAs

Share to Recombination, Genetic

Share to Transcription Activator-Like Effector Nucleases

Source

Identifiers

PMID: 27590580
DOI: 10.1016/j.bbrc.2016.08.152

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Improved antiviral efficacy using TALEN-mediated homology directed recombination to introduce artificial primary miRNAs into DNA of hepatitis B virus.PMID 27590580Read ↗

An Efficient Antiviral Strategy for Targeting Hepatitis B Virus Genome Using Transcription Activator-Like Effector NucleasesSemantic proximity Read ↗

Progress With Developing Use of Gene Editing To Cure Chronic Infection With Hepatitis B Virus.Semantic proximity Read ↗

Gene-Editing and RNA Interference in Treating Hepatitis B: A ReviewSemantic proximity Read ↗

Gene Therapy for Chronic HBV—Can We Eliminate cccDNA?Semantic proximity Read ↗

The progress of molecules and strategies for the treatment of HBV infectionSemantic proximity Read ↗

Progress and Prospects of Anti-HBV Gene Therapy DevelopmentSemantic proximity Read ↗

Functional cure of hepatitis B requires silencing covalently closed circular and integrated hepatitis B virus DNASemantic proximity Read ↗

Evaluation of Interfering RNA Efficacy in Treating Hepatitis B: Is It Promising?Semantic proximity Read ↗

CRISPR/Cas9 cleavage of viral DNA efficiently suppresses hepatitis B virusSemantic proximity Read ↗

Advances with RNAi-Based Therapy for Hepatitis B Virus InfectionSemantic proximity Read ↗

AAV-Mediated Delivery of Zinc Finger Nucleases Targeting Hepatitis B Virus Inhibits Active ReplicationSemantic proximity Read ↗

Recent Progress and Future Prospective in HBV Cure by CRISPR/CasSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.